ARVINAS Business Summary

Arvinas, Inc. (ARVN) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic collaboration agreements, licensing fees, and milestone payments from major pharmaceutical partners, most notably Pfizer and Novartis. The company’s business model is centered on its proprietary Proteolysis-Targeting Chimera (PROTAC) platform, which leverages the body’s natural ubiquitin-proteasome system to selectively degrade disease-causing proteins. Its primary business segments are organized around therapeutic areas, specifically oncology—led by its late-stage breast cancer candidate vepdegestrant (ARV-471), which has a PDUFA date of June 5, 2026—and neuroscience, targeting conditions like Parkinson’s disease and progressive supranuclear palsy. Arvinas competes directly with other protein degradation and targeted therapy firms such as Alector, Prelude Therapeutics, Iovance Biotherapeutics, and Erasca. As a pioneer in the PROTAC space, Arvinas maintains a leading market position by transitioning from a platform-discovery entity to a late-stage clinical organization with a robust pipeline of previously "undruggable" targets. The company was founded in 2013 by Dr. Craig M. Crews, a renowned Yale University professor who pioneered the PROTAC technology. As of February 13, 2026, the leadership team is led by President and CEO Randy Teel, Ph.D., who was appointed on February 12, 2026, after serving as the company’s Chief Business Officer and playing a pivotal role in its 2018 IPO. Other key executives include Chief Financial Officer Andrew Saik, Chief Scientific Officer Angela M. Cacace, Ph.D., and Chief Medical Officer Noah Berkowitz, M.D., Ph.D. The Board of Directors is chaired by Briggs Morrison, M.D., and includes former CEO John Houston, Ph.D., who remains a consultant to the firm. Notable institutional backing and board representation come from prominent life science investors such as Canaan Partners, 5AM Ventures, and OrbiMed, alongside recent strategic influence from activist investor Logos Global Management.